HomeCompareHAITY vs PFE

HAITY vs PFE: Dividend Comparison 2026

HAITY yields 0.53% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $29.5K in total portfolio value· pulled ahead in Year 8
10 years
HAITY
HAITY
● Live price
0.53%
Share price
$8.00
Annual div
$0.04
5Y div CAGR
-14.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$11.38
Full HAITY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — HAITY vs PFE

📍 PFE pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHAITYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HAITY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HAITY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HAITY
Annual income on $10K today (after 15% tax)
$44.96/yr
After 10yr DRIP, annual income (after tax)
$9.67/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,310.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HAITY + PFE for your $10,000?

HAITY: 50%PFE: 50%
100% PFE50/50100% HAITY
Portfolio after 10yr
$34.8K
Annual income
$13,135.05/yr
Blended yield
37.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

HAITY
No analyst data
Altman Z
1.0
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HAITY buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHAITYPFE
Forward yield0.53%6.13%
Annual dividend / share$0.04$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-14.4%13.2%
Portfolio after 10y$20.0K$49.6K
Annual income after 10y$11.38$26,258.71
Total dividends collected$250.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HAITY vs PFE ($10,000, DRIP)

YearHAITY PortfolioHAITY Income/yrPFE PortfolioPFE Income/yrGap
1$10,745$45.28$9,153$693.39+$1.6KHAITY
2$11,536$38.92$8,593$849.25+$2.9KHAITY
3$12,377$33.43$8,336$1,066.78+$4.0KHAITY
4$13,272$28.69$8,437$1,384.80+$4.8KHAITY
5$14,226$24.61$9,013$1,875.40+$5.2KHAITY
6$15,243$21.11$10,306$2,680.72+$4.9KHAITY
7$16,328$18.09$12,820$4,101.38+$3.5KHAITY
8← crossover$17,487$15.50$17,673$6,826.70$186.00PFE
9$18,724$13.28$27,543$12,591.86$8.8KPFE
10$20,046$11.38$49,560$26,258.71$29.5KPFE

HAITY vs PFE: Complete Analysis 2026

HAITYStock

Haitong Securities Co., Ltd. operates as a securities company primarily in Mainland China, Hong Kong, and Europe. It operates through Wealth Management, Investment Banking, Asset Management, Trading and Institution, Finance Lease, and Others segments. The Wealth Management segment offers securities and futures brokering and dealing, investment consulting, and wealth management services, as well as financial services, such as margin financing, securities lending, stock pledge, etc. The Investment Banking segment provides sponsoring and underwriting services in equity and debt capital markets; financial consulting services, which include merger and assets restructuring services; and services related to the national equities exchange and quotations. The Asset Management segment offers investment management services on investment products comprising asset, fund, and private equity management to individual, corporate, and institutional clients. The Trading and Institution segment provides stock sales and trading, prime brokerage, and stock lending and research services in financial markets; market-making services for fixed income, currency and commodity products, futures and options, and derivatives on various exchanges; and investment funds and private equity projects. The Finance Lease segment offers financial solutions that include finance and operating lease, factoring, entrustment loans, and related consulting services. The Others segment provides warehouse receipts pledge, pricing, and market-making services, as well as services related to risk management. The company also offers fund trading, distribution, and management services; financial and commodity futures contracts broking and dealing services; investment advisory and management services; banking services; and real estate development, property management, and catering management services. Haitong Securities Co., Ltd. was founded in 1988 and is based in Shanghai, the People's Republic of China.

Full HAITY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this HAITY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HAITY vs SCHDHAITY vs JEPIHAITY vs OHAITY vs KOHAITY vs MAINHAITY vs JNJHAITY vs MRKHAITY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.